ArticleDermatology practical & conceptual2025
Comparative Efficacy and Tolerability of Imiquimod 3.75% Cream vs 5-Fluorouracil 4% cream in the Treatment of Actinic Keratosis: A Split-Face Study.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionActinic keratosis (AK) is a common precancerous skin lesion that arises on chronically UV-exposed skin and that can progress to keratinocyte carcinoma.
objectiveThe aim of this study was to compare the efficacy, safety, local skin reaction, time to wound healing, and patient preference of imiquimod (IMQ) 3.75% vs 5-fluorouracil (5-FU) 4% cream treatment for AKs.
methodsTwo symmetrical contralateral areas of approximately 25 cm
resultsThe mean variation (ΔT0-T1) of AKs was not significantly different in patients treated with IMQ 3.75% vs 5-FU 4% (P = 0.35). The mean LSR was not significantly different between patients treated with IMQ 3.75% and those with 5-FU 4% (p=0.63). No difference in cosmetic outcome was observed in the two groups. Patient preference was equally distributed between the treatments. The mean time to wound healing after the end of the treatment was similar with IMQ 3.75% and with 5-FU 4% (P = 0.83).
conclusionsThis study reports a non-superiority of efficacy, tolerability, wound-healing time, and cosmetic outcome of topical IMQ 3.75% treatment compared to topical 5-FU 4% treatment in AK management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.